Placenta-specific protein 1

Genomics

PLAC1 is located on the long arm of the X-chromosome at Xq26.3. The gene consists of six exons spanning nearly 200Kb (GRCh38/hgs38; X:134,565,838 - 134,764,322). The entire coding sequence plus the 3' UTR and part of the 5' UTR constitute exon 6 while exons 1 – 5 contain variously spliced elements of the rest of the 5'UTR including two independently regulated promoters.

These two promoters, termed P1 (or distal) and P2 (or proximal) are located in exons 1 and 4 respectively. They have been shown to produce transcripts simultaneously though P1 transcription predominates in cancers and P2 transcription predominates in placentae.

Phylogenetics

From its initial description, the consensus is that PLAC1 is highly conserved and that this conservation reflects an important role in the establishment and maintenance of the placenta. A detailed study of the PLAC1 gene and protein among 54 placental mammal species representing twelve crown orders confirms a high level of conservation under the control of strict purifying selection.

Function

Discovery of PLAC1 resulted from an examination of the region around the human hypoxanthine ribosyltransferase 1 (HPRT) gene aimed at determining whether or not a placenta-specific protein was encoded there. This question was raised because the region was believed to be involved in both placental and fetal pathologies. Once identified, PLAC1 and its mouse ortholog Plac1 were found to be expressed throughout gestation. It was quickly established that PLAC1 expression is specific to trophoblast cells and that it is a critical element in establishing and maintaining a normal placenta. Expression was further localised to the apical region of the syncytiotrophoblast, the leading, invasive part of the developing embryo. PLAC1 expression terminates at the onset of labor and PLAC1 mRNAs clear the peripheral maternal circulatory system soon after delivery.

The PLAC1 gene is protein-coding and involved in the development of the placenta from trophoblast cells. This gene is specifically found on the X chromosome in an area that controls placenta development. It has been suggested that large deletions from this area of the X chromosome leads to retardation in the fetal growth process as well as early fetal death. PLAC1 is believed to be a mainly regulatory gene and is expressed the most between the 22nd and 40th week of pregnancy in humans. The knockout model generated for the PLAC1 gene suggested that mice were infertile when PLAC1 was inactivated or died late in gestation or shortly after birth, indicating that PLAC1 is a significant gene that greatly contributes to the viability of an organism. The molecular basis for the impact of PLAC1 is unknown, although it is clear the absence of this gene results in infertile or inviable offspring.

Recognition that PLAC1 plays an important role in first establishing the placenta and, subsequently, in maintaining it throughout gestation leads to the idea that PLAC1 may play a role in gestational issues from infertility to premature birth. An important contribution to this idea is the observation that a Plac1 knockout mouse model exhibited both placentomegaly in the dams and growth restriction in the pups. Numerous human gestational issues have been associated with abnormal PLAC1 expression including intrauterine growth restriction (IUGR), premature birth, implantation failure, and preeclampsia. Several of these studies have sought to develop PLAC1 assays into diagnostic tools with mixed success.

Cancer

While it has been clearly established that PLAC1 is truly placenta-specific, almost from the outset it was also clear that PLAC1 is co-opted in human cancers. The first evidence that PLAC1 is co-opted in cancer was published in 2006. Since then, PLAC1 expression has been demonstrated in more than a dozen human cancers and in at least one hundred human cancer cell lines. Among the cancers in which PLAC1 expression is evident are gastric cancers, colon/colorectal cancers, liver cancers, pancreatic cancers, lung cancers, and breast cancers. In nearly all cases, PLAC1 expression is associated with poor clinical outcomes. Nowhere is this more true than in cancers of the male and female reproductive tract. That is, prostate cancer, uterine cancer, ovarian cancer and cervical cancer all have demonstrated a positive correlation between PLAC1 expression and prognosis.

In 2005, PLAC1 expression in differentiating fibroblasts was shown to be regulated by fibroblast growth factor 7 (FGF7). This regulatory relationship has since been shown to be central to Akt Serine/Threonine kinase 1-mediated cancer cell proliferation. PLAC1 forms a cell surface complex with FGF7 and the FGFR2IIIb receptor which then activates a cascade leading to Akt phosphorylation. Expression of PLAC1is, in turn, partially determined by the p53 tumor suppressor. PLAC1 expression is suppressed by wild-type p53 but increases in the presence of mutated or absent p53.

Immunotherapy

PLAC1 is classified as a "cancer-testis antigen" as it is preferentially expressed in trophoblasts and tumors. In addition to results associating PLAC1 expression with risk of various cancers as well as with prognosis, the ability of PLAC1 to elicit an immune response suggests that its specificity could be harnessed therapeutically. One group in particular is pioneering the potential. Using anti-PLAC1/drug conjugates they have shown that PLAC1-based immunotherapy is highly promising.

References

References

1. (November 2011). "RXRα and LXR activate two promoters in placenta- and tumor-specific expression of PLAC1". Placenta.
2. (August 2012). "Plac1 (placenta-specific 1) is essential for normal placental and embryonic development". Molecular Reproduction and Development.
3. (2014). "Placenta-specific protein 1 is conserved throughout the Placentalia under purifying selection". TheScientificWorldJournal.
4. (September 2016). "PLAC1 is involved in human trophoblast syncytialization". Reproductive Biology.
5. (July 2005). "PLAC1 expression increases during trophoblast differentiation: evidence for regulatory interactions with the fibroblast growth factor-7 (FGF-7) axis". Molecular Reproduction and Development.
6. (October 2014). "Role of placenta-specific protein 1 in trophoblast invasion and migration". Reproduction.
7. (December 2002). "PLAC1, a trophoblast-specific gene, is expressed throughout pregnancy in the human placenta and modulated by keratinocyte growth factor". Molecular Reproduction and Development.
8. (2008). "The evolution, regulation, and function of placenta-specific genes". Annual Review of Cell and Developmental Biology.
9. (2005). "Rapid clearance of mRNA for PLAC1 gene in maternal blood after delivery". Fetal Diagnosis and Therapy.
10. (2014). "The nexus of prematurity, birth defects, and intrauterine growth restriction: a role for plac1-regulated pathways". Frontiers in Pediatrics.
11. (October 2017). "Expression of placental regulatory genes is associated with fetal growth". Journal of Perinatal Medicine.
12. (1978). "[Biological studies with enkephalins and endorphins and their analogs]". Annales de l'Anesthésiologie Française.
13. (October 2019). "Association of Higher Maternal Serum Levels of Plac1 Protein with Intrauterine Growth Restriction". Zeitschrift für Geburtshilfe und Neonatologie.
14. (January 2005). "Lower maternal PLAC1 mRNA in pregnancies complicated with vaginal bleeding (threatened abortion <20 weeks) and a surviving fetus". Clinical Chemistry.
15. (June 2007). "PLAC1 mRNA levels in maternal blood at induction of labor correlate negatively with induction-delivery interval". European Journal of Obstetrics, Gynecology, and Reproductive Biology.
16. (2011). "Circulating Anti-PLAC1 Antibodies during Pregnancy and in Women with Reproductive Failure: A Preliminary Analysis.". International Scholarly Research Notices.
17. (April 2013). "Preliminary evidence for high anti-PLAC1 antibody levels in infertile patients with repeated unexplained implantation failure". Placenta.
18. (October 2018). "Placenta-specific 1 regulates oocyte meiosis and fertilization through furin". FASEB Journal.
19. (August 2020). "Placenta specific protein-1 in recurrent pregnancy loss and in ''In Vitro'' Fertilisation failure: a prospective observational case-control study". Journal of Obstetrics and Gynaecology.
20. (March 2006). "Increased plasma mRNAs of placenta-specific 1 (PLAC1) and glial cells-missing 1 (GCM1) in mothers with pre-eclampsia". Hiroshima Journal of Medical Sciences.
21. (August 2007). "Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia". Prenatal Diagnosis.
22. (April 2011). "Plasma mRNA concentrations of placenta-specific 1 (PLAC1) and pregnancy associated plasma protein A (PAPP-A) are higher in early-onset than late-onset pre-eclampsia". The Journal of Obstetrics and Gynaecology Research.
23. (2014). "Circulating mRNA for the PLAC1 gene as a second trimester marker (14-18 weeks' gestation) in the screening for late preeclampsia". Fetal Diagnosis and Therapy.
24. (2018). "Maternal placi protein levels in early- and late-onset preeclampsia". Ginekologia Polska.
25. (November 2019). "Declined placental PLAC1 expression is involved in preeclampsia". Medicine.
26. (April 2020). "Syncytiotrophoblast extracellular microvesicle profiles in maternal circulation for noninvasive diagnosis of preeclampsia". Scientific Reports.
27. (April 2006). "[PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients]". Beijing da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences.
28. (January 2011). "MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis". PLOS ONE.
29. (June 2012). "Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer". Amino Acids.
30. (December 2010). "[Expression of PLAC1/CP1 genes in primary colorectal carcinoma and its clinical significance]". Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology.
31. (March 2014). "Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1". Journal of Gastroenterology.
32. (November 2015). "New tumour antigen PLAC1/CP1, a potentially useful prognostic marker and immunotherapy target for gastric adenocarcinoma". Journal of Clinical Pathology.
33. (November 2017). "Detection of circulating tumor cells by reverse transcription‑quantitative polymerase chain reaction and magnetic activated cell sorting in the peripheral blood of patients with hepatocellular carcinoma". Molecular Medicine Reports.
34. (January 2017). "Oncogenic function of Plac1 on the proliferation and metastasis in hepatocellular carcinoma cells". Oncology Reports.
35. (June 2017). "Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma". Tumour Biology.
36. (January 2018). "Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer". Oncology Reports.
37. (October 2007). "A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes". Cancer Research.
38. (October 2009). "Selective activation of trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform 2". The Journal of Biological Chemistry.
39. (December 2013). "NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells". BMC Cancer.
40. (April 2018). "PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer". Oncology Letters.
41. (August 2018). "Cancer/testis antigen-Plac1 promotes invasion and metastasis of breast cancer through Furin/NICD/PTEN signaling pathway". Molecular Oncology.
42. (2018). "PLAC1 as a serum biomarker for breast cancer". PLOS ONE.
43. (December 2014). "High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma". Cancer Immunology, Immunotherapy.
44. (October 2017). "Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy". Scientific Reports.
45. (2013). "The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines". Obstetrics and Gynecology International.
46. (August 2009). "Expression and serum immunoreactivity of developmentally restricted differentiation antigens in epithelial ovarian cancer". Cancer Immunity.
47. (May 2017). "p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers". International Journal of Oncology.
48. (May 2017). "Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor Histology". International Journal of Gynecological Cancer.
49. (May 2020). "PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation". Oncotarget.
50. (September 2013). "T antigen transformation reveals Tp53/RB-dependent route to PLAC1 transcription activation in primary fibroblasts". Oncogenesis.
51. (2020). "Expression of Human Placenta-specific 1 (PLAC1) in CHO-K1 Cells". Avicenna Journal of Medical Biotechnology.